Protara Therapeutics, Inc. TARA
3.28
(0.07)
(2.09%)
as of 25 Sep
- Market cap
- $198.0M
- P/E
- 0.0×
Follow TARA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
13.69 | 14.58 | 15.69 | 10.97 |
Net Debt/EBITDA |
9.30 | 7.74 | 6.98 | 6.01 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.94 | 0.98 | 1.20 | 0.71 | |
Capex/Depreciation |
(0.01) | 0.02 | 0.00 | 0.87 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.29) | (0.40) | (0.37) | (0.26) | |
Cash per Share |
3.14 | 3.63 | 2.36 | 2.34 | |
Shareholders Equity per Share |
3.13 | 4.59 | 3.15 | 2.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.13 | 4.59 | 3.15 | 2.64 | |
Free Cash Flow |
(12.46) | (16.97) | (21.34) | (15.72) | |
Working Capital |
125.74 | 148.57 | 131.08 | 132.83 | |
Capital Expenditures |
0.00 | (0.02) | — | (0.33) | |
Net Current Asset Value |
123.30 | 146.45 | 129.28 | 131.37 | |
| Other line items | |||||
Quick Ratio |
13.39 | 14.22 | 15.22 | 10.70 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.29) | (0.40) | (0.37) | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Average Payables |
3.40 | 3.95 | 3.17 | 4.98 | |
Average Assets |
119.36 | 195.46 | 180.24 | 166.51 | |
Average Common Equity |
107.04 | 181.77 | 169.85 | 152.87 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates